A patient-centered look at what people expect from Botox treatment, from subtle facial movement and visible improvement to provider choice, safety, satisfaction, value, and the decision to repeat treatment.
Audience: Botox Patient
Countries: 6
Completion Rate: 72.3%
SGID: 8986092
-Hero findings
– Quick Read — Key Findings
Cosmetic botulinum toxin treatment is designed to temporarily reduce muscle activity in selected areas. For patients, however, the decision is often more personal: how different will I look, will the result still feel like me, how long will it last, and what happens if I do not like it?
The American Academy of Dermatology explains that targeted botulinum toxin injections can soften lines while preserving natural facial expression, with effects commonly lasting about three to four months, and the American Society of Plastic Surgeons similarly describes cosmetic botulinum toxin as temporary, with visible results developing over several days. The MDForLives data place those practical questions at the center of the patient journey: natural movement and natural-looking improvement lead the key outcome and repeat-treatment questions, while expected results, provider expertise, and safety all weigh more heavily than cost when people consider who or what to choose.
38.6% say natural facial movement is the treatment outcome that matters most, ahead of noticeably fewer wrinkles at 32.9%.
The motivation question tells a similar story from another angle: reducing facial wrinkles is the leading reason for considering Botox at 47.1%, 30.0% want to look more refreshed, 15.7% want to prevent deeper wrinkles, and 7.1% want improved symmetry. Together the findings suggest patients want improvement they can see without making the face feel over-treated, the desired change is real, but so is the wish to keep movement and familiarity.
40.0% say expected treatment results most influence their provider or treatment choice.
Results, expertise, and safety together dominate the decision, and the AAD’s patient guidance recommends asking who will perform the injections, how much experience they have, what results are realistic, and whether personal health factors change the risk profile. The low ranking of cost in this single-select question does not mean cost is irrelevant, only that when respondents must choose one main influence, confidence in the result and the person delivering it carries more weight.
48.6% say treatment met expectations, while 12.9% say it was better than expected and 11.4% say it was below expectations.
Another 27.1% select “treatment not yet received,” which matters because the group contains both people judging an actual result and people still anticipating one, so expectations and experience sit side by side in the same decision journey. This is where clear consultation counts, a patient may be weighing wrinkle reduction, facial movement, duration, safety, and the speed of the visible effect at once, and a result can be clinically acceptable yet still feel disappointing if the expected degree of change was different.
42.9% say they would request a provider correction after an unsatisfactory result, while 30.0% would wait for the result to fade.
Only 10.0% would stop aesthetic treatments altogether, so an unsatisfactory outcome does not automatically end interest, the first question is usually whether the result can be reviewed, corrected, or allowed to wear off. Because botulinum toxin effects develop and fade over time, timing matters when judging a result, and professional guidance advises contacting the treating professional with any concerns, especially unexpected symptoms or asymmetry.
40.0% say natural-looking improvement would most influence repeat treatment, while 43.5% say longer-lasting effects are the future improvement that would influence them most.
Perceived value follows the same pattern: visible improvement leads the “worth the cost” question at 40.0%, then duration of results at 32.9%, overall experience at 14.3%, and safety at 12.9%. Looking ahead, longer-lasting effects lead at 43.5%, followed by more personalized plans at 27.5%, greater precision at 18.8%, and faster recovery with fewer side effects at 10.1%.
The open responses reinforce these themes: patients want subtle, natural-looking results, clearer guidance before and after treatment, confidence in provider competence, consistent duration, and an experience that feels comfortable, safe, and worth the cost, with some describing good outcomes and minimal discomfort and others raising concerns about duration, price, or pre-treatment uncertainty.
The survey shows a workday shaped by uncertainty: pain and sensory symptoms interrupt concentration, acute treatment does not always restore function quickly, and common workplace exposures can make an attack harder to manage, yet many respondents keep working and adapt by keeping plans flexible, resting when treatment fails, or changing how much they take on.
The bigger story is that migraine management at work needs two things together, treatment that controls symptoms reliably enough, and a workplace that allows practical flexibility when it does not. More effective acute therapy is the most requested improvement, but flexible schedules, break access, and accommodations remain important because even good treatment cannot guarantee every attack behaves predictably.
You have read the summary
Discover the complete research behind these insights, or become part of future studies with MDForLives.
Direct answers to common questions about symptoms, treatment, productivity, triggers, and workplace support.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
